(Q44256504)

1 December 2017

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma (English)

1 reference

1 December 2017

5

Cezary Szczylik

1 reference

1 December 2017

Arkadiusz Z Dudek

1

1 reference

1 December 2017

Jakub Zolnierek

series ordinal

2

1 reference

1 December 2017

Anu Dham

series ordinal

3

1 reference

1 December 2017

Bruce R Lindgren

series ordinal

4

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

1 December 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

1 December 2017

115

1 reference

1 December 2017

61-67

1 reference

1 December 2017

1

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

1 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24009

21 January 2018

Identifiers

DOI

10.1002/CNCR.24009

1 reference

1 December 2017

1 reference